Aptose Biosciences

BiopharmaTrend.com

BPT Crunch

Companies on the Cutting Edge of Healthcare Innovations

back to Marketplace

Aptose Biosciences

Founded
2014

Patents
8

Clinical Trials
7

Publications
6

Technologies

Antisense Oligonucleotides

Aptose Biosciences is a science-driven clinical-stage biotechnology company developing first-in-class targeted agents to address unmet clinical need in multiple hematologic malignancies.

Posts Mentioning This Company

Antisense Oligonucleotides Make Sense

Antisense oligonucleotides (ASOs) are short (about 12 to 25 nucleotides long), synthetic single strands of DNA or RNA that are complementary to a chosen sequence. They can alter RNA and reduce, restore, or modify protein expression. ASOs interact with proteins on the surface of cells and enter the cytoplasm. Then …

R&D Platform

CG-806, our oral mutation-agnostic FLT3/BTK inhibitor, is being developed for the treatment of patients with certain B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and certain non-Hodgkin’s lymphomas (NHL) who are resistant or intolerant to conventional treatments.

CG-806 is also being developed for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML), including the emerging populations resistant to approved targeted therapies.

APTO-253, our first-in-class MYC Inhibitor, is being developed for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).